Advertisement
Canada markets closed

  • S&P/TSX

    21,807.37
    +98.93 (+0.46%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CAD/USD

    0.7275
    +0.0012 (+0.16%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • Bitcoin CAD

    87,448.92
    +3,440.01 (+4.09%)
     

  • CMC Crypto 200

    1,366.97
    +54.34 (+4.14%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • RUSSELL 2000

    1,947.66
    +4.70 (+0.24%)
     

  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     

  • NASDAQ

    15,282.01
    -319.49 (-2.05%)
     

  • VOLATILITY

    18.71
    +0.71 (+3.94%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

Abbvie raises sales outlook of two immunology drugs to more than $17.5 billion in 2025

Reuters
Updated ·1 min read
A sign stands outside a Abbvie facility in Cambridge

(Reuters) -AbbVie Inc on Tuesday raised its 2025 sales forecast of its newer immunology drugs Skyrizi and Rinvoq to more than $17.5 billion as it hopes to replace the loss of revenue from its blockbuster rheumatoid arthritis drug Humira.

The company's previous sales outlook for Skyrizi and Rinvoq in 2025 was more than $15 billion.

AbbVie also expects peak sales of the drugs to exceed $21 billion in 2027. The two drugs are part of the company's long-term growth strategy to offset Humira's loss of exclusivity.

The drugmaker has been in contract negotiations with insurers and pharmacy benefit managers for Humira for this year, and said in October that pricing of its rivals would determine the drug's sales this year.

(Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli and Shounak Dasgupta)